Abstract
Aim To explore the expression of long noncoding RNA (LncRNA) LUCAT1 in adult patients with Crohn's disease (CD) and evaluate the relationship between LncRNA LUCAT1 and the disease activity in Chinese patients with CD. Methods Patients with CD and healthy participants (≥18 years old) were enrolled in this study between January 2018 and December 2019. The expression of LncRNA LUCAT1 in plasma samples was evaluated by quantitative reverse transcription-polymerase chain reaction. Basic characteristics of patients with CD were collected, including gender, age, clinical stage, disease behavior, disease location, C-reactive protein (CRP), platelet (PLT), erythrocyte sedimentation rate (ESR), fecal calprotectin (FC), Crohn's disease activity index (CDAI) score, and simplified Crohn's disease endoscopic score (SES-CD). Results In total, 168 patients with CD and 65 healthy participants (≥18 years old) were enrolled in this study. Among them, ninety patients with clinically active CD, seventy-eight patients with CD in clinical remission, forty-eight patients with endoscopically active CD, thirty patients with endoscopically inactive CD, and sixty-five healthy participants. LncRNA LUCAT1 was increased in plasma of patients with CD compared with the control group. The plasma LncRNA LUCAT1 level of patients with CD both in the clinical and endoscopic active phase was higher than that of both the clinical and endoscopic remission phase. The plasma level of LncRNA LUCAT1 in patients with CD was positively correlated with ESR, CRP, FC, CDAI, and SES-CD. There was no significant correlation between the level of LUCAT1 and platelets. The plasma LncRNA LUCAT1 level in patients with CD had significant differences between severe active patients and mild/moderate active patients. Conclusion The plasma LncRNA LUCAT1 is positively associated with the disease activity in patients with CD, and it may act as a noninvasive biomarker to identify the degree of disease activity.
Highlights
Patients with Crohn’s disease (CD), a type of inflammatory bowel disease (IBD), suffer from many gastrointestinal symptoms, including diarrhea, abdominal pain, vomiting, and weight loss [1]
Among the 78 patients with CD in clinical remission, we found 11 patients in endoscopically active CD and 30 patients with endoscopically inactive CD (Table 3)
The results showed higher plasma LUCAT1 levels in patients with CD when compared with healthy controls, and the LUCAT1 levels were positively correlated with the disease activity
Summary
Patients with Crohn’s disease (CD), a type of inflammatory bowel disease (IBD), suffer from many gastrointestinal symptoms, including diarrhea, abdominal pain, vomiting, and weight loss [1]. These symptoms are nonspecific, and, the correlation between the symptomatic and the objective measures of disease activity is poor [2]. Previous studies have demonstrated that long noncoding RNAs (LncRNAs) could be considered to act as novel biomarkers for the disease [5]. A previous study reported that there were 438 and 745 differentially expressed LncRNAs in patients with CD, compared with healthy individuals
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
